NRXPW
NRX Pharmaceuticals, Inc.
Key Financials
Revenue
$1.2M
↑ Infinity%
Net Income
$-28622000
↓ 13.9%
Operating Income
$-16224000
↑ 12.3%
EPS (Diluted)
$-0.60
↑ 69.7%
Total Assets
$13.0M
↑ 254.9%
Total Liabilities
$28.9M
↑ 7.5%
Shareholders' Equity
$-15937000.00
↑ 31.4%
Cash & Equivalents
$7.8M
↑ 440.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 9/16/2026 | View on SEC |
| 8-K | 9/14/2026 | View on SEC |
| 8-K | 8/17/2026 | View on SEC |
| 10-Q | 8/14/2026 | View on SEC |
| 8-K | 8/7/2026 | View on SEC |
| 8-K | 7/22/2026 | View on SEC |
| 8-K | 6/4/2026 | View on SEC |
| 424B5 | 6/3/2026 | View on SEC |
| 8-K | 6/2/2026 | View on SEC |
| 424B5 | 6/2/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | NRXPW |
| Company Name | NRX Pharmaceuticals, Inc. |
| CIK | 1719406 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 484-254-6134 |